Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
asset sale
CRO
Charles River sells CDMO and discovery assets in strategic pivot
The CRO is offloading its contract manufacturing operation and some of its European discovery services, which brought in $287 million last year.
Darren Incorvaia
Feb 25, 2026 1:54pm
2 biotechs run out of road
Dec 17, 2025 11:38am
Tempest strikes all-stock deal for Factor’s CAR-T pipeline, CEO
Nov 19, 2025 12:22pm
WuXi sharpens focus by selling off clinical research units
Oct 28, 2025 12:27pm
I-Mab unveils new name, strategy, asset and Hong Kong IPO plans
Oct 17, 2025 10:45am
Servier supercharges neuro pipeline with $450M deal
Sep 8, 2025 2:30am
